Skin Cancer

I wish my doctors knew more about the emotional aspects of cancer and were given more time with me.

Melanoma survivor vents about her "procedures" and discusses digital mole mapping.

Suresh S. Ramalingam, a professor of medical oncology at the Winship Cancer Institute of Emory University, comments on the difference in toxicities associated with immunotherapy.

Former U.S. president Jimmy Carter provided an update on his health today in a press conference, announcing that he has melanoma.

The U.S. Food & Drug Administration has approved Odomzo (sonidegib) for the treatment of patients with locally advanced basal cell carcinoma who have experienced a recurrence of this condition after surgery or radiation, or who weren't eligible for those therapies.

A grumpy and grateful cancer survivor reflects on her neuropathy and lymphedema.

Even my own family doesn't get it, and I'm glad. Two-time cancer survivor describes an isolating, fear-of-recurrence moment.

Several key areas in the treatment of melanoma include the selection of appropriate immunotherapy regimens based on PD-L1 status and improvement of surgical practices.

Melanoma has been at the forefront of the immuno-oncology revolution. This trend continued at the 2015 annual meeting of ASCO, a gathering of nearly 30,000 oncology professionals in Chicago.

Optimism helps when cancer is diagnosed, advises TV newsman and melanoma survivor Sam Donaldson.

A cancer survivor discusses a problem, even with good intentions, of the public's lack of cancer education.

Protective clothing can help prevent skin cancers by blocking the sun's ultraviolet rays.

A melanoma survivor shares her experience and ideas.

When melanoma metastacizes, the lymph node to which it has spread is typically removed. But what if micrometastases are found in other nearby lymph nodes? Should patients undergo a complete dissection, or removal, of all the nodes in the area?

A breast cancer survivor shares ways she copes with fear of recurrence while waiting for her latest mammogram results.

Significant strides have been made in the treatment of patients with immunotherapies and targeted therapies. However, determining which therapies are best for which patients and how to treat patients who don't respond or stop responding to these new therapies is still a challenge.

A breast cancer and melanoma survivor reflects on the emotions and experiences after surgeries, chemotherapy and radiation are completed.

For those with a history of non-melanoma skin cancer (NMSC), reducing their risk of recurrence can be as simple as taking the vitamin B3 pill nicotinamide.

A breast cancer and melanoma survivor shares her thoughts on time as well as her biopsy results.

In a combined decision, members of the FDA's Oncologic Drugs Advisory Committee and Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) voted 22-1 to recommend approval of T-VEC.

The FDA has assigned a priority review designation to Opdivo (nivolumab) as a treatment for previously untreated patients with unresectable or metastatic melanoma.

A breast cancer and melanoma survivor shares her perspective on living with "wait and watch."

Pembrolizumab (Keytruda) elicited significantly better outcomes compared with ipilimumab (Yervoy) in a randomized phase 3 trial of patients with advanced melanoma.

Frontline immunotherapy with Opdivo (nivolumab) plus Yervoy (ipilimumab) delayed disease progression by 60 percent compared with Yervoy alone in patients with advanced melanoma.

Kevin B. Kim, of the California Pacific Medical Center, explains how patients with melanoma who are in remission can get back into a normal, daily routine while still taking precautions.

At age 22, Megan Miller was diagnosed with basal cell carcinoma, a common form of skin cancer that can be easily treated. But a year later, she was diagnosed with melanoma.

In 1995, Sam Donaldson, ABC news veteran, found a lump that ultimately led to a diagnosis of melanoma.

The development of agents targeting the PD-1 immune checkpoint in the treatment of patients with advanced melanoma is progressing rapidly.

A trial comparing frontline Keytruda (pembrolizumab) with Yervoy (ipilimumab) for the treatment of advanced melanoma has met its progression-free survival and overall survival endpoints.

The FDA has granted a priority review to the MEK inhibitor cobimetinib for use in combination with the BRAF inhibitor Zelboraf to treat patients with BRAF V600–positive advanced melanoma.